Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irinotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 6/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.59 |
| ▸ | GLA | P06280 | 2/20 | 0.59 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.59 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.59 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.59 |
| ▸ | MMP1 | P03956 | 1/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.59 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | NCOA3 | Q9Y6Q9 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irinotecan SCHEMBL17102276 | 0.95 | GAA (0.54) | GAACYP3A4GLASLC22A2SLC22A1 | |
| Teniposide SCHEMBL4763786 | 0.91 | GAA (0.49) | GAACYP3A4GLASLC22A2SLC22A1 | |
| Irinotecan SCHEMBL20521877 | 0.85 | GLA (0.70) | GAACYP3A4GLASLC22A2SLC22A1 | |
| Etoposide SCHEMBL1276328 | 0.84 | SMN1; SMN2 (0.57) | GAACYP3A4GLASLC22A2SLC47A2 | |
| Etoposide SCHEMBL18921683 | 0.82 | GAA (0.61) | GAACYP3A4GLASMN1; SMN2LMNA | |
| Etoposide SCHEMBL14931202 | 0.82 | GAA (0.61) | GAACYP3A4GLASMN1; SMN2LMNA | |
| Teniposide SCHEMBL5324539 | 0.79 | SMN1; SMN2 (0.58) | GAACYP3A4GLASLC22A2SLC47A2 | |
| SCHEMBL20807092 | 0.79 | GLA (0.55) | GAACYP3A4GLASLC22A2SLC22A1 | |
| SCHEMBL20807126 | 0.78 | GLA (0.55) | GAACYP3A4GLASLC22A2SLC22A1 | |
| SCHEMBL18774809 | 0.78 | GLA (0.55) | GAACYP3A4GLASLC22A2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024082026-A1 | METHODS FOR DETECTING AGGRESSIVE PROSTATE CANCER | MINOMIC INTERNATIONAL LTD. (AU) | 2024-04-25 | — | — | WO | disclosed |
| US-20230055103-A1 | METHODS FOR THE DIAGNOSIS OF LUNG CANCER | INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (ES) | 2023-02-23 | — | — | US | disclosed |
| EP-3941533-A1 | METHODS FOR THE DIAGNOSIS OF LUNG CANCER | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron (ES) | 2022-01-26 | — | — | EP | disclosed |
| US-10987669-B2 | Apparatus and method for detection of tumour cells and circulating tumour cells | MEDCOM TECH, S.A. (ES) | 2021-04-27 | — | — | US | disclosed |
| WO-2020188023-A1 | METHODS FOR THE DIAGNOSIS OF LUNG CANCER | FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (ES) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020136281-A1 | METHODS FOR THE PROGNOSIS OF PROSTATE CANCER | ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE (ES) | 2020-07-02 | — | — | WO | disclosed |
| EP-3674421-A1 | METHODS FOR THE PROGNOSIS OF PROSTATE CANCER | Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE (ES) | 2020-07-01 | — | — | EP | disclosed |
| EP-3657173-A1 | BIOMARKERS OF PROSTATE CANCER AGGRESSIVENESS | Institut d'Investigació Sanitària Pere Virgili (ES) | 2020-05-27 | — | — | EP | disclosed |
| US-20200055048-A1 | OPTOFLUIDIC DEVICE AND METHOD FOR DETECTING CIRCULATING TUMOUR CELLS | FUNDACIÓ EURECAT (ES) | 2020-02-20 | — | — | US | disclosed |
| EP-3607299-A1 | OPTOFLUIDIC DEVICE AND METHOD FOR DETECTING CIRCULATING TUMOUR CELLS | Universitat Rovira i Virgili (ES) | 2020-02-12 | — | — | EP | disclosed |
| WO-2008123867-A9 | GENE EXPRESSION PROFILING FOR IDENTIFICATION, MONITORING, AND TREATMENT OF BREAST CANCER | SOURCE PRECISION MEDICINE INC (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008143639-A2 | GENE EXPRESSION PROFILING FOR IDENTIFICATION, MONITORING, AND TREATMENT OF CERVICAL CANCER | SOURCE PRECISION MEDICINE, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008123867-A1 | GENE EXPRESSION PROFILING FOR IDENTIFICATION, MONITORING, AND TREATMENT OF BREAST CANCER | SOURCE PRECISION MEDICINE, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008123866-A2 | GENE EXPRESSION PROFILING FOR IDENTIFICATION, MONITORING AND TREATMENT OF OVARIAN CANCER | SOURCE PRECISION MEDICINE, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008121132-A2 | GENE EXPRESSION PROFILING FOR IDENTIFICATION, MONITORING, AND TREATMENT OF PROSTATE CANCER | SOURCE PRECISION MEDICINE, INC. D/B/A SOURCE MDX (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008063414-A9 | GENE EXPRESSION PROFILING FOR IDENTIFICATION, MONITORING, AND TREATMENT OF COLORECTAL CANCER | SOURCE PRECISION MEDICINE INC (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008063414-A2 | GENE EXPRESSION PROFILING FOR IDENTIFICATION, MONITORING, AND TREATMENT OF COLORECTAL CANCER | SOURCE PRECISION MEDICINE, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063413-A2 | GENE EXPRESSION PROFILING FOR IDENTIFICATION, MONITORING, AND TREATMENT OF LUNG CANCER | SOURCE PRECISION MEDICINE, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| EP-1807410-A1 | COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF NEOPLASIA | NIPRI Limited (GB) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006046071-A1 | COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF NEOPLASIA | NIPRI LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |